A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone

[1]  P. Dubreuil,et al.  Recent advances in the understanding and therapeutic management of mastocytosis , 2019, F1000Research.

[2]  L. Pleyer,et al.  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions , 2019, Haematologica.

[3]  J. Khoury,et al.  Recent Updates on Chronic Myelomonocytic Leukemia , 2018, Current Hematologic Malignancy Reports.

[4]  D. Nagorney,et al.  Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty‐nine patients , 2018, American journal of hematology.

[5]  A. Tefferi,et al.  Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance , 2017, American journal of hematology.

[6]  G. Nilsson,et al.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. , 2017, Cancer research.

[7]  A. Tefferi,et al.  DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemia , 2017, American journal of hematology.

[8]  M. Cazzola,et al.  Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. , 2016, Blood.

[9]  A. Tefferi,et al.  Next‐generation sequencing in systemic mastocytosis: Derivation of a mutation‐augmented clinical prognostic model for survival , 2016, American journal of hematology.

[10]  F. Awan,et al.  Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. , 2016, The New England journal of medicine.

[11]  A. Tefferi,et al.  CME Information , 2016, Stahl's Illustrated Sleep and Wake Disorders.

[12]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[13]  M. Stratton,et al.  Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents , 2016, Nature Communications.

[14]  A. Tefferi,et al.  Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia , 2015, Blood Cancer Journal.

[15]  Dong Chen,et al.  Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. , 2015, American journal of clinical pathology.

[16]  E. Solary,et al.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients , 2014, Leukemia.

[17]  D. Birnbaum,et al.  Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Djokic.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors , 2010 .

[19]  A. Tefferi,et al.  Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. , 2009, Blood.

[20]  D. Rosenthal,et al.  Chronic myelomonocytic leukemia. , 1990, Leukemia.